MindBio Therapeutics Corp. announced positive top line data from its world-first take-home microdosing depression clinical trial using MB22001. The completion of this landmark and highly successful Phase 2a clinical trial is a major inflection point for the Company as it moves to late-stage pharma drug development.

MindBio has achieved a significant milestone as the only organisation in the world that is running multiple clinical trials with Government and Regulatory approvals for take-home use and handling of a psychedelic medicine by trial patients out in the community, specifically a proprietary self-titratable form of Lysergic Acid Diethylamide (LSD) in microdoses designed for take home use (MB22001). MindBio has collected tens of thousands of data points, over 3 years from clinical trials including psychometric data, speech analytics, sleep, biometric, activity data, EEG, ECG, PK/PD including DNA sampling. MindBio is building a proprietary treatment model that is scalable, safe and effective and can be tailored to patients as a first line treatment for Depression.

proprietary drug candidate MB22001 is self-titratable, allowing patients to dose up or down depending on the individual's tolerance. The Phase 2a clinical trial demonstrated excellent safety, adherence and tolerance profile in doses tested. This was consistent with the Phase 1 trial results.